AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38191814 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with various anastomosis techniques (intracorporeal, side-to-side, isoperistaltic)
Number of subjects: 788
Study 38191814 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic approach
Number of subjects: 788
Study 38191821 — intervention group
Group type: COMPARATOR
Intervention: Magnetization transfer ratio (MTR) in patients with T2D (0.211 ± 0.07)
Number of subjects: 52
Study 38191821 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer ratio (MTR) in patients with T1D
Number of subjects: 52
Study 38191821 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetization transfer ratio (MTR) in patients with T2D
Number of subjects: 52
Study 38191968 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 30
Study 38192233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously at weeks 0 and 4
Number of subjects: 220
Study 38192233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 38192233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg subcutaneously every 12 weeks after week 12
Number of subjects: 220
Study 38192247 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated retinal oximetry in patients with significant carotid stenosis
Number of subjects: 50
Study 38192247 — intervention group
Group type: COMPARATOR
Intervention: Non-stenotic vessels (control group)
Number of subjects: 50
Study 38192435 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD-Impact Scale (ADPKD-IS)
Number of subjects: 3409
Study 38192435 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD-Urinary Impact Scale (ADPKD-UIS)
Number of subjects: 3409
Study 38192435 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs)
Number of subjects: 3409
Study 38192435 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 3409
Study 38192588 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing impairment (≥25 dB threshold)
Number of subjects: 7135
Study 38192592 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg every 28 days until progression or unacceptable toxicity
Number of subjects: 50
Study 38193018 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 164
Study 38193018 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 164
Study 38193069 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab prophylaxis
Number of subjects: 3
Study 38193069 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruation-related quality of life
Number of subjects: 3
Study 38193069 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstruation heaviness
Number of subjects: 3
Study 38193158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), 2 to 4 sessions
Number of subjects: 3
Study 38193250 — intervention group
Group type: EXPERIMENTAL
Intervention: PALLiON intervention (physician education program, patient-centred care pathway, patient symptom reporting)
Number of subjects: 616
Study 38193250 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 616
Study 38193250 — intervention group
Group type: EXPERIMENTAL
Intervention: PALLiON intervention
Number of subjects: 616
Study 38193250 — intervention group
Group type: EXPERIMENTAL
Intervention: PALLiON intervention and Usual care (control)
Number of subjects: 616
Study 38193259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera toxin sensitization
Number of subjects: 45
Study 38193259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil emulsion sensitization
Number of subjects: 45
Study 38193259 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 45
Study 38193327 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5178
Study 38193336 — intervention group
Group type: EXPERIMENTAL
Intervention: Care2Sleep intervention (n=15 dyads)
Number of subjects: 30
Study 38193336 — intervention group
Group type: COMPARATOR
Intervention: Information-only control group (n=15 dyads)
Number of subjects: 30
Study 38193426 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (SCS) plus conventional medical management (CMM)
Number of subjects: 216
Study 38193426 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM) alone
Number of subjects: 216
Study 38193596 — intervention group
Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi®)
Number of subjects: 25
Study 38194016 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab (0.3, 1.0, 3.0, and 10.0 mg/kg every 2 weeks in 28-day cycles for up to 2 years)
Number of subjects: 29
Study 38194016 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab
Number of subjects: 29
Study 38194047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (200/300 mg) every 4 weeks for 16 weeks
Number of subjects: 125
Study 38194047 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks for 16 weeks
Number of subjects: 125
Study 38194118 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention for cancer prevention education
Number of subjects: 0
Study 38194162 — intervention group
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa (80, 240, or 320 µg/kg for TC; 240 or 320 µg/kg for TAC)
Number of subjects: 232
Study 38194162 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg)
Number of subjects: 232
Study 38194231 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by chemoradiation
Number of subjects: 304
Study 38194231 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation followed by consolidation chemotherapy
Number of subjects: 304
Study 38194231 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical tumor response grade (CCR vs NCR)
Number of subjects: 304
Study 38194233 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative-intent therapy for colorectal cancer
Number of subjects: 450
Study 38194233 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-General (rapid version) score increase
Number of subjects: 450
Study 38194233 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy increase
Number of subjects: 450
Study 38194233 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood deprivation index
Number of subjects: 450
Study 38194236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation (CR) - 10 center-based supervised exercise sessions plus counseling in 4 to 6 weeks, followed by support at home via telephone calls and text messages through weeks 8 to 12.
Number of subjects: 191
Study 38194236 — intervention group
Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (CR) - 18 to 22 sessions with exercises and education in 8 to 12 weeks.
Number of subjects: 191
Study 38194236 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Cardiac Rehabilitation (CR)
Number of subjects: 191
Study 38194236 — intervention group
Group type: COMPARATOR
Intervention: Standard Cardiac Rehabilitation (CR)
Number of subjects: 191
Study 38194247 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) scenario followed by an educational video and a repetition of the VR scenario; duration: not specified.
Number of subjects: 15
Study 38194257 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice warning during simulated driving (Study 0)
Number of subjects: 48
Study 38194257 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice warning during driving with T1DM participants (Study 1)
Number of subjects: 48
Study 38194257 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice warning during real-world driving with T1DM participants (Study 2)
Number of subjects: 48
Study 38194257 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice warning across all studies
Number of subjects: 48
Study 38194272 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (5 doses over 28 days)
Number of subjects: 21
Study 38194272 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) control
Number of subjects: 21
Study 38194603 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation combined with Alternating Synchronized and Nonsynchronized Intermittent Theta Burst Stimulation
Number of subjects: 0
Study 38194603 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38194610 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized risk-prediction model (IRMMa)
Number of subjects: 1933
Study 38194610 — intervention group
Group type: COMPARATOR
Intervention: International Staging System (ISS)
Number of subjects: 1933
Study 38194610 — intervention group
Group type: COMPARATOR
Intervention: Revised-ISS
Number of subjects: 1933
Study 38194610 — intervention group
Group type: COMPARATOR
Intervention: R2-ISS
Number of subjects: 1933
Study 38194613 — intervention group
Group type: EXPERIMENTAL
Intervention: NROSS screening (two-stage screening strategy with CA-125 and TVS)
Number of subjects: 7856
Study 38194613 — intervention group
Group type: EXPERIMENTAL
Intervention: NROSS screening
Number of subjects: 7856
Study 38194616 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Abemaciclib plus endocrine therapy
Number of subjects: 0
Study 38194616 — intervention group
Group type: COMPARATOR
Intervention: Control group (endocrine therapy alone)
Number of subjects: 0
Study 38194689 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC2 mutations (23 distinct mutations, including 15 novel variants)
Number of subjects: 54
Study 38194689 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC2 mutations
Number of subjects: 54
Study 38194689 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC2 mutant proteins
Number of subjects: 54
Study 38194692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel infusion (0.6 × 10^8-6 × 10^8 chimeric antigen receptor-positive viable T cells)
Number of subjects: 97
Study 38195076 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent tumor-treating fields (TTFields) with radiation and temozolomide
Number of subjects: 1
Study 38195076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment after recurrence
Number of subjects: 1
Study 38195162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult male offspring of AAA patients
Number of subjects: 943
Study 38195162 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult female offspring of AAA patients
Number of subjects: 943
Study 38195162 — intervention group
Group type: COMPARATOR
Intervention: Male controls
Number of subjects: 943
Study 38195162 — intervention group
Group type: COMPARATOR
Intervention: Female controls
Number of subjects: 943
Study 38195162 — intervention group
Group type: EXPERIMENTAL
Intervention: Male adult offspring of AAA patients
Number of subjects: 943
Study 38195162 — intervention group
Group type: EXPERIMENTAL
Intervention: Female adult offspring of AAA patients
Number of subjects: 943
Study 38195170 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (MRI combined with targeted biopsies)
Number of subjects: 111000
Study 38195170 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 111000
Study 38195170 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 111000
Study 38195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Purrble robot intervention
Number of subjects: 168
Study 38195171 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 168
Study 38195172 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment including endoscopy with duodenal biopsies
Number of subjects: 853
Study 38195172 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for CD by serology
Number of subjects: 853
Study 38195172 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to hospital records and the Norwegian Patient Registry (NPR)
Number of subjects: 853
Study 38195172 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment after at least 1 year including repeated standard serological testing, endoscopy and tissue sampling
Number of subjects: 853
Study 38195322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (intravenous) - 1 mg on Day 1, 2 mg on Day 8, 60 mg on Day 15/Cycle 2 Day 1, and 30 mg from Cycle 3 Day 1 onwards for a median of eight 21-day cycles.
Number of subjects: 218
Study 38195348 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-mg IV infusion of lefamulin
Number of subjects: 13
Study 38195348 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg oral tablet of lefamulin
Number of subjects: 13
Study 38195348 — intervention group
Group type: COMPARATOR
Intervention: Comparison with prior studies in healthy volunteers
Number of subjects: 13
Study 38195348 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 13
Study 38195390 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with concerns about COVID-19
Number of subjects: 1478
Study 38195390 — intervention group
Group type: COMPARATOR
Intervention: Women without concerns about COVID-19
Number of subjects: 1478
Study 38195390 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 1478
Study 38195396 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock Drawing Test (CDT)
Number of subjects: 554
Study 38195438 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial supraclavicular lymph node irradiation (M-SCLI)
Number of subjects: 1650
Study 38195438 — intervention group
Group type: COMPARATOR
Intervention: Medial plus posterolateral supraclavicular lymph node irradiation (entire SCL irradiation, E-SCLI)
Number of subjects: 1650
Study 38195471 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoneurological symptom cluster assessment using network analyses at baseline, 6, 12, and 24 months.
Number of subjects: 480
Study 38195473 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Impact community-based lifestyle change program
Number of subjects: 74
Study 38195486 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth device (n=36)
Number of subjects: 70
Study 38195486 — intervention group
Group type: COMPARATOR
Intervention: No eHealth device (n=34)
Number of subjects: 70
Study 38195550 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol (RC) levels in quartiles
Number of subjects: 5597
Study 38195550 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordant high RC/low LDL-C group
Number of subjects: 5597
Study 38195568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary sulfur amino acid restriction (SAAR) ~ 2 g/day
Number of subjects: 59
Study 38195568 — intervention group
Group type: COMPARATOR
Intervention: Control group ~ 5.6 g/day sulfur amino acids
Number of subjects: 59
Study 38195586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 240
Study 38195586 — intervention group
Group type: COMPARATOR
Intervention: Intravenous aspirin
Number of subjects: 240
Study 38195600 — intervention group
Group type: EXPERIMENTAL
Intervention: HEARTS-aligned components including training health workers, strengthening access to medications, risk-based management, team-based care, and electronic monitoring.
Number of subjects: 100
Study 38195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal brain stimulation
Number of subjects: 0
Study 38195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal brain stimulation
Number of subjects: 0
Study 38195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral brain stimulation
Number of subjects: 0
Study 38195605 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study 38195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Upper Extremity (FM-UE) score
Number of subjects: 0
Study 38195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of FM-UE (A) related to muscle synergies
Number of subjects: 0
Study 38195605 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale
Number of subjects: 0
Study 38195728 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced packed red blood cell (PRBC) transfusion
Number of subjects: 23
Study 38195732 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 70
Study 38195732 — intervention group
Group type: COMPARATOR
Intervention: Control group (without periodontal disease)
Number of subjects: 70
Study 38195752 — intervention group
Group type: EXPERIMENTAL
Intervention: Amph-Peptides-2P and Amph-CpG-7909
Number of subjects: 25
Study 38195922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadir-to-regain time ≤1 day
Number of subjects: 654
Study 38195922 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative weight loss ≤-50 percent-days
Number of subjects: 654
Study 38195921 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC growth failure in-hospital
Number of subjects: 590
Study 38195921 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC growth failure at 2 years
Number of subjects: 590
Study 38196014 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin
Number of subjects: 222
Study 38196092 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (daily and occasional)
Number of subjects: 42935
Study 38196092 — intervention group
Group type: EXPERIMENTAL
Intervention: Snus use
Number of subjects: 42935
Study 38196092 — intervention group
Group type: COMPARATOR
Intervention: Never smokers
Number of subjects: 42935
Study 38196092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use (daily, occasional, and snus)
Number of subjects: 42935
Study 38196092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 42935
Study 38196118 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-I Plus
Number of subjects: 33
Study 38196118 — intervention group
Group type: COMPARATOR
Intervention: ABPM
Number of subjects: 33
Study 38196118 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-I Plus and ABPM
Number of subjects: 33
Study 38196129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 1084
Study 38196129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1084
Study 38196286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Antiplatelet Therapy
Number of subjects: 0
Study 38196458 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 220
Study 38196458 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 220
Study 38196617 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the blind field
Number of subjects: 48
Study 38196617 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the intact field
Number of subjects: 48
Study 38196639 — intervention group
Group type: EXPERIMENTAL
Intervention: TFC+ISF+P4P (financial incentives for MIBI implementation)
Number of subjects: 428
Study 38196639 — intervention group
Group type: COMPARATOR
Intervention: TFC+ISF (control condition)
Number of subjects: 428
Study 38196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body intervention as an adjunct to MOUD
Number of subjects: 303
Study 38196650 — intervention group
Group type: COMPARATOR
Intervention: MOUD (standard treatment)
Number of subjects: 303
Study 38196655 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit plus one-time economic incentive
Number of subjects: 1332
Study 38196655 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term counseling and economic incentive program
Number of subjects: 1332
Study 38196756 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched treatment (PET) lettuce
Number of subjects: 42
Study 38196756 — intervention group
Group type: COMPARATOR
Intervention: Control lettuce
Number of subjects: 42
Study 38196756 — intervention group
Group type: COMPARATOR
Intervention: Control and PET lettuce
Number of subjects: 42
Study 38196889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg every 4 weeks for 52 weeks
Number of subjects: 0
Study 38196889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38196889 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 38196940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait asymmetry in spatiotemporal and kinetic variables
Number of subjects: 836
Study 38196940 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg length discrepancy and fat mass as determinants of asymmetry
Number of subjects: 836
Study 38196969 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis (n = 45)
Number of subjects: 92
Study 38196969 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (n = 47)
Number of subjects: 92
Study 38197000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release pregabalin tablet (YHD1119), once-daily dosing.
Number of subjects: 0
Study 38197040 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative understanding of experiences related to cancer cachexia (CC) through semi-structured interviews
Number of subjects: 0
Study 38197040 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment recommendations by oncologist for anorexia and weight loss
Number of subjects: 0
Study 38197040 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience of anorexia and weight loss
Number of subjects: 0
Study 38197138 — intervention group
Group type: EXPERIMENTAL
Intervention: sitravatinib plus tislelizumab
Number of subjects: 0
Study 38197225 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dry mouth
Number of subjects: 1291
Study 38197296 — intervention group
Group type: EXPERIMENTAL
Intervention: Xevinapant plus radiotherapy
Number of subjects: 700
Study 38197296 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus radiotherapy
Number of subjects: 700
Study 38197636 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended vital sign checks (EVs) from every 4 hours to every 6 hours
Number of subjects: 50
Study 38197636 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-reported sleep disturbance
Number of subjects: 50
Study 38197642 — intervention group
Group type: EXPERIMENTAL
Intervention: Frail patients (mFI ≥2)
Number of subjects: 261
Study 38197642 — intervention group
Group type: COMPARATOR
Intervention: Nonfrail patients (mFI = 0-1)
Number of subjects: 261